| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$378 |
South Erregulla Power Project Update
|
16 Mar 2026 8:30AM |
$0.110 |
$0.105 |
fallen by
4.55%
|
|
STX - Price-sensitive ASX Announcement
Full Release
Key Points
- 35% increase in BRCP for 2028/29 to $488,500 per MW per annum.
- 15 km single circuit overhead power line completed.
- Power station work package nearing completion.
- Dry commissioning activities have commenced.
- Project on track for completion by October 1, 2026.
- Strike expects full 85 MW capacity allocation for 2028/29.
- Project supports system reliability and renewable integration within WA's electricity market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Narryer Metals Limited (NYM) ORDINARY FULLY PAID |
Materials |
$12 |
PTR: Positive Metallurgical Perf.and Strong Drill Results
|
16 Mar 2026 8:30AM |
$0.020 |
$0.058 |
risen by
190%
|
|
NYM - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive metallurgical performance
- Strong drilling results in Rosewood Titanium Project
- Batch 4 shows high-grade mineralisation
- Large bulk sample RM04 confirms high-grade average
- Continued exploration and metallurgical testing
- Focus on economic and development potential
- Plant design and preliminary cost assessments underway
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PTR Minerals Ltd (PTR) ORDINARY FULLY PAID |
Materials |
$40 |
Positive Metallurgical Performance and Strong Drill Results
|
16 Mar 2026 8:30AM |
$0.185 |
$0.100 |
fallen by
45.95%
|
|
PTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive metallurgical performance at Rosewood project.
- High recovery of Heavy Minerals through conventional processing.
- Production of high-grade titanium products.
- Strong drill results indicating high-grade mineralisation.
- Ongoing metallurgical and processing evaluation activities.
- Resource estimation planned for Q2 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gateway Mining Limited (GML) ORDINARY FULLY PAID |
Materials |
$109 |
Drilling Commenced at Great Western
|
16 Mar 2026 8:30AM |
$0.074 |
$0.047 |
fallen by
36.49%
|
|
GML - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling has commenced at Gateway's top priority, the Great Western gold target.
- This is the first systematic drilling program at the Great Western site.
- The site features a 16 km dolerite strike length with gold-in-soil anomalies.
- Gateway is well-capitalised, with significant cash reserves and liquid assets.
- The drilling program is expected to take three months to complete.
- Great Western displays geological similarities to significant Eastern Goldfields deposits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$99 |
Dimerix to Conduct Review of ACTION3 Statistical Assumptions
|
16 Mar 2026 8:29AM |
$0.350 |
$0.165 |
fallen by
52.86%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- Dimerix Limited to conduct a blinded review of ACTION3 Phase 3 study data to confirm statistical assumptions.
- The blinded review will verify the study remains adequately powered for its primary endpoint.
- The ACTION3 Phase 3 study focuses on the efficacy and safety of DMX-200 in patients with FSGS.
- The study has passed several reviews with no safety issues or protocol changes requested.
- FDA has confirmed the primary endpoint's suitability for supporting traditional approval.
- The review aims to ensure the study can demonstrate a treatment effect without revealing treatment assignments.
- Results from the review are expected to be available in April 2026.
- DMX-200, a chemokine receptor antagonist, is under development for treatment in conjunction with existing hypertension therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flagship Minerals Limited (FLG) ORDINARY FULLY PAID |
Materials |
$60 |
Corporate Presentation
|
16 Mar 2026 8:29AM |
$0.295 |
$0.185 |
fallen by
37.29%
|
|
| Syrah Resources Limited (SYR) ORDINARY FULLY PAID |
Materials |
$290 |
Tesla offtake alleged default cure date extended
|
16 Mar 2026 8:28AM |
$0.170 |
$0.125 |
fallen by
26.47%
|
|
SYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Syrah Resources faces an alleged default under the Tesla offtake agreement.
- Original cure date set for March 16, 2026.
- Cure date extended to June 1, 2026.
- Extension subject to United States Department of Energy consent.
- Collaboration between Syrah and Tesla to resolve the issue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$14 |
Half Yearly Report and Accounts
|
16 Mar 2026 8:27AM |
$0.024 |
$0.013 |
fallen by
45.83%
|
|
| BNK Banking Corporation Limited (BBC) ORDINARY FULLY PAID |
Financials |
$29 |
Notification of cessation of securities - BBC
|
16 Mar 2026 8:27AM |
$0.280 |
$0.240 |
fallen by
14.29%
|
|
| South32 Limited (S32) ORDINARY FULLY PAID |
Materials |
$20,279 |
Mozal Aluminium Placed on Care and Maintenance
|
16 Mar 2026 8:24AM |
$4.410 |
$4.520 |
risen by
2.49%
|
|
| Minerals 260 Limited (MI6) ORDINARY FULLY PAID |
Materials |
$1,951 |
Euroz Hartleys Conference and Site Visit Presentation
|
16 Mar 2026 8:22AM |
$0.620 |
$0.860 |
risen by
38.71%
|
|
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$350 |
Nova Winter Freight Haul Underway
|
16 Mar 2026 8:20AM |
$0.765 |
$0.765 |
fallen by
0%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,372 |
Annual General Meeting and Director Nominations
|
16 Mar 2026 8:20AM |
$4.510 |
$5.080 |
risen by
12.64%
|
|
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,691 |
Update - Notification of buy-back - ORA
|
16 Mar 2026 8:19AM |
$1.905 |
$1.380 |
fallen by
27.56%
|
|
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,947 |
GYG Co-CEO Update
|
16 Mar 2026 8:19AM |
$18.050 |
$19.400 |
risen by
7.48%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$49 |
Neurizon announces leadership transition
|
16 Mar 2026 8:19AM |
$0.096 |
$0.065 |
fallen by
32.29%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon Therapeutics Limited announced a leadership transition.
- Dr. Michael Thurn resigned as Managing Director and Chief Executive Officer.
- Dr. Thurn's resignation is effective from 16 March 2026, with a notice period until July 2026.
- During the transition, Dr. Thurn will continue as a Non-Executive Director.
- Mr. Sergio Duchini will serve as Interim Executive Chair until a new CEO is appointed.
- A global search for a new CEO is underway with the help of Coulter Partners.
- Neurizon Therapeutics is a clinical-stage biotechnology company focused on treatments for neurodegenerative diseases.
- The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS.
- NUZ-001 is not yet approved for commercial use.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$4,616 |
Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging
|
16 Mar 2026 8:19AM |
$11.290 |
$13.600 |
risen by
20.46%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix resubmits NDA for TLX101-Px to FDA.
- TLX101-Px is aimed at imaging recurrent/progressive gliomas.
- FDA requested additional data for the resubmission.
- TLX101-Px has orphan drug and fast track designations.
- The agent targets LAT1 for potential use in glioma diagnostics.
- Telix is collaborating globally for data on TLX101-Px.
- The company seeks to address unmet needs in brain cancer imaging.
- Telix operates globally with headquarters in Melbourne, Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,947 |
Update - Notification of buy-back - GYG
|
16 Mar 2026 8:19AM |
$18.050 |
$19.400 |
risen by
7.48%
|
|
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$726 |
Update - Notification of buy-back - OML
|
16 Mar 2026 8:19AM |
$0.930 |
$1.375 |
risen by
47.85%
|
|
| NuEnergy Gas Limited (NGY) ORDINARY FULLY PAID |
Energy |
$54 |
Half Yearly Report and Accounts
|
16 Mar 2026 8:19AM |
$0.038 |
$0.028 |
fallen by
26.32%
|
|
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$386 |
Update - Notification of buy-back - KGN
|
16 Mar 2026 8:19AM |
$3.730 |
$4.040 |
risen by
8.31%
|
|
| Atturra Limited (ATA) ORDINARY FULLY PAID |
Information Technology |
$169 |
Update - Notification of buy-back - ATA
|
16 Mar 2026 8:19AM |
$0.560 |
$0.460 |
fallen by
17.86%
|
|
| Ore Resources Limited (OR3) ORDINARY FULLY PAID |
Materials |
$66 |
Proposed issue of securities - OR3
|
16 Mar 2026 8:18AM |
$0.067 |
$0.080 |
risen by
19.40%
|
|
| Bio-Gene Technology Ltd (BGT) ORDINARY FULLY PAID |
Materials |
$8 |
Sumitomo & Nakashima to launch Qcide products in Japan
|
16 Mar 2026 8:18AM |
$0.035 |
$0.022 |
fallen by
37.14%
|
|
BGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Bio-Gene Technology Ltd (BGT) partners with Sumitomo Corporation and Nakashima Trading Co. for Qcide® launch in Japan.
- Qcide is a 100% natural insecticide developed by Bio-Gene from Eucalyptus cloeziana.
- Target market is household nuisance insect pests in Japan, expected launch in late 2026.
- Non-binding term sheet signed with definitive agreements expected by April/May 2026.
- Bio-Gene to produce Qcide oil in Queensland, Australia.
- Sumitomo to manage ordering, trade financing, transportation, and import approval.
- Nakashima will handle formulation, packaging, promotion, and supply to retail.
- Japanese home insecticide market is estimated at US$1B annually with growing demand for natural products.
- Qcide is OMRI listed, approved for use in certified organic production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ore Resources Limited (OR3) ORDINARY FULLY PAID |
Materials |
$66 |
Expansion of Coolgardie Gold and Lithium Project
|
16 Mar 2026 8:18AM |
$0.067 |
$0.080 |
risen by
19.40%
|
|
OR3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Ore Resources Ltd acquired four prospecting licenses, expanding their Coolgardie Gold and Lithium Project.
- The acquisition increases Ore's landholding in the Coolgardie area to over 80 km².
- The Avoca Prospect, a mineralised trend approximately 300m long, is included in the new tenure.
- Historical exploration data reveals several high-grade gold intercepts at the Avoca Prospect.
- Ore Resources plans systematic exploration, including soil sampling and geophysical surveys, to commence in early Q3 2026.
- The new tenure is strategically located near several gold processing facilities, enhancing its commercial potential.
- Ore Resources is well-funded with A$10.7 million and no debt as of December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.